Haleon
Haleon plc (FTSE 100: HLN) is listed on the London Stock Exchange, it is a British multinational consumer healthcare company and a global leader in over the counter medicines.
Haleon was spun out of GSK and established on the 18th July 2022, it is the largest consumer healthcare business in the world.
The business is owned by GSK (13%) & Pfizer (32%) and the rest making up institutional funds and private investors.
Haleon’s purpose is to “improve the everyday health of everyone, everywhere”.
The company’s products are divided into 5 categories:
- Pain Relief
- Respiratory Health
- Digestive Health
- Oral Health
- Vitamins, minerals & supplements (VMS)
Haleon Brands
There are 5 power categories, then within each, there are local strategic brands.
- Pain Relief – Advil, Excedrin, Fenbid, Panadol, Voltaren,
- Respiratory Health – Contac, Flonase, Otrivin, Theraflu.
- Digestive Health – Eno, Fenistil, Nicolette, Nexium, Tums.
- Oral Health – Aquafresh, biotene, Parodontax, Polident, Sensodyne.
- Vitamins, minerals & supplements (VMS) – Caltrate, Centrum, Emergen-C
Following the spin out from GSK the business was carrying quite an amount of debt, so in the early stages the business did not pay or distribute any dividends.
Haleon’s initial intention to pay down debt has been well executed, enabling the business to start distributing bi-annual dividends from 2022.
At the proposed business spin-out we were entitled to be included in the newly formed Haleon shares through holding our original 100 GSK shares.
Each shareholder would stand to gain one share of HLN for every held GSK share.
The reason we opted for the GSK share split was after reading and digesting all the information about the new business, and by understanding where and how it would be positioned on the global stage did we choose to proceed.
We perceive Haleon plc to be a well positioned business within the future healthcare space, where it should be able to add value to the existing portfolio of brands whilst growing both reoccurring revenues and income.
Being aware of its current brands, size, together with its ability to build on existing and add new brands and products, I foresee Haleon being a popular dividend stock in portfolios of the future.
Haleon Dividends
As Haleon is a newly spun out business, then the dividend history is somewhat limited to just three years:
2025 £0.0220 pence
2024 £0.0660 pence
2023 £0.0600 pence
2022 £0.0.24 pence
Projections for the final year end distribution of a dividend will be announced early in 2026, subject to financials, debt obligations and repayments.
An interim dividend for 2025 was announced at £0.0220 pence per share, and was paid on 18/09/25, going ex-dividend 14/08/25)
We look forward to seeing Haleon growing the future dividends, subject to reducing the debt and providing sales continue to grow.
P/E: 23.26 (12/01/26)
Dividend Yield: 1.82% (12/01/26)
Total income received to date is just £17.20
Further dividend analysis can be viewed in the file below:
Alternatively, click on the link here to see how the Haleon payments contributes to the total 2025 income.
HLN
Website Disclaimer:
Please remember that all investments can rise and fall in value, therefore you may get back less then you originally invested.
This website or webpage is not a suggestion to purchase or invest in any stocks / equities and is presented purely for research analysis.
Should you be unsure of any investment whether it be purchasing shares or equities directly, funds or investment trackers, you should seek independent financial advice from a qualified financial advisor.
All logos and Trademarks are the property of the company covered in this article. We only use logos/pictures to assist investors identify the Brand/s and encompassing products.
